Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Selenium, in the form of inorganic Sodium Selenite, may be useful for treating existing
prostate cancer. This idea is based on data from our laboratory showing that 1) prostate
cancer cells are more sensitive to Selenium (Sodium Selenite)-induced apoptosis than normal
prostate epithelial cells, 2) Selenite induces significant growth inhibition of well
established prostate cancer tumors in mice at doses that have no detectable toxicity, and 3)
Selenite disrupts AR signaling, and that the inhibition of AR expression and activity by
Selenite occurs via a redox mechanism involving GSH, superoxide, and Sp1. Altogether, these
findings suggest that Selenium may be useful in a variety of potential indications in the
natural history of prostate cancer, including both hormone sensitive and castrate resistant
prostate cancer, as a single agent, or in combination with radiation, chemotherapy or
conventional hormone therapy. Selenite is a potential novel inhibitor of AR expression and
function in prostate cancer.